Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $70.21 USD
Change Today +0.27 / 0.39%
Volume 1.9M
MYL On Other Exchanges
As of 12:44 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

mylan nv (MYL) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/15 - $76.69
52 Week Low
08/13/14 - $44.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MYLAN NV (MYL)

mylan nv (MYL) Details

Mylan N.V., through its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and the manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form (FDF) products for the antiretroviral (ARV) market and non-ARV FDF products that are marketed to third parties. It offers generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. Further, the company manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. was founded in 1961 and is headquartered in Potters Bar, Hertfordshire.

25,000 Employees
Last Reported Date: 03/2/15
Founded in 1961

mylan nv (MYL) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: $1.2M
President, Executive Director and Member of S...
Total Annual Compensation: $890.4K
Executive Chairman and Chairman of Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
President of Mylan North America
Total Annual Compensation: $545.2K
Compensation as of Fiscal Year 2014.

mylan nv (MYL) Key Developments

Mylan N.V. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:00 PM

Mylan N.V. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:00 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States.

Mylan May Consider Buying Teva

Mylan N.V. (NasdaqGS:MYL) is not willing to sell itself to Teva Pharmaceutical Industries Limited (NYSE:TEVA), Mylan’s Executive Chairman, Robert Coury said. The official added that the company would consider buying that company down the road. The company has been steadfast in its refusal to combine with Teva and is instead encouraging shareholders to support its own $34 billion unsolicited offer for over-the-counter Perrigo Company Public Limited Company (NYSE:PRGO). Teva made an unsolicited $40 billion bid for Mylan in April 2015, and it was rejected. Teva said recently that it will move ahead with its plans to acquire Mylan if the Perrigo deal is not completed.

Mylan N.V. Enters into Amendment No. 1 to the Revolving Credit Agreement

On May 1, 2015, Mylan Inc. entered into Amendment No. 1 to the Revolving Credit Agreement dated as of December 19, 2014, among the Borower, Mylan N.V, certain lenders and issuing banks and Bank of America, N.A., as administrative agent. The Revolving Amendment provides that, following the closing of the company's offer for the entire issued and to be issued share capital of Perrigo Company plc, the financial covenant in the Revolving Credit Agreement will be modified as follows: (i) for the four fiscal quarters following the closing of the Perrigo Proposal, the company will be required to maintain a ratio of consolidated total indebtedness as of the end of any quarter to consolidated EBITDA for the trailing four quarters not to exceed 4.75 to 1.00, (ii) for each of the subsequent two fiscal quarters, the company will be required to maintain a Leverage Ratio not to exceed 4.25 to 1.00, and (iii) for any fiscal quarter thereafter, the company will be required to maintain a Leverage Ratio not to exceed 3.75 to 1.00. The Revolving Amendment also amends the event of default provisions to provide that any change of control or change of control put rights under any indebtedness of Perrigo or its subsidiaries that are triggered as a result of the closing of the Perrigo Proposal will not result in an event of default so long as the company or its subsidiaries refinances such indebtedness within 30 days of the closing of the Perrigo Proposal or makes any change of control offer required by the terms of such indebtedness and purchases all notes validly tendered pursuant thereto, respectively.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:US $70.22 USD +0.28

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,821 JPY -0.50
Becton Dickinson and Co $142.75 USD +0.34
Perrigo Co PLC $199.38 USD +1.12
Shire PLC 5,540 GBp +35.00
WW Grainger Inc $246.19 USD -0.41
View Industry Companies

Industry Analysis


Industry Average

Valuation MYL Industry Range
Price/Earnings 33.2x
Price/Sales 3.7x
Price/Book 3.8x
Price/Cash Flow 39.7x
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at